FeDeriCa Trial Results on the Fixed-Dose Subcutaneous Pertuzumab/Trastuzumab in HER2+ Breast Cancer: What Are the Pharmacokinetic, Efficacy, and Safety Outcomes Compared to the Standard Intravenous Administration?
Comments 1
Login to view comments.
Click here to Login
